MaaT Pharma Announces New Appointments to the Board and Executive Team

LYON, France–(BUSINESS WIRE)—- $MAAT–Regulatory News: MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients with cancer, today announced new appointments to its Board and Executive team. Board of Directors Karim Dabbagh, PhD, is appointed as Chairman and independent Director, succeeding Jean-Marie Lefèvre who will continue to serve as a Board m

Recent Articles